004310 — Hyundai Pharmaceutical Co Balance Sheet
0.000.00%
- KR₩97bn
- KR₩142bn
- KR₩176bn
- 31
- 34
- 21
- 14
Annual balance sheet for Hyundai Pharmaceutical Co, fiscal year end - November 30th, KRW millions except per share, conversion factor applied.
2020 November 30th | 2021 November 30th | 2022 November 30th | 2023 November 30th | 2024 November 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 19,884 | 21,916 | 33,779 | 18,291 | 10,277 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 42,358 | 40,336 | 42,461 | 38,973 | 38,652 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 80,503 | 84,896 | 101,643 | 85,473 | 79,562 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 29,567 | 29,261 | 28,601 | 29,436 | 37,446 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 157,502 | 163,857 | 181,159 | 154,629 | 156,396 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 51,779 | 45,850 | 80,696 | 65,334 | 58,687 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 67,361 | 77,257 | 94,604 | 69,968 | 77,322 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 90,141 | 86,600 | 86,555 | 84,661 | 79,074 |
| Total Liabilities & Shareholders' Equity | 157,502 | 163,857 | 181,159 | 154,629 | 156,396 |
| Total Common Shares Outstanding |